Therapeutic Advances in Respiratory Disease. Original Research
|
|
- Trevor Bates
- 5 years ago
- Views:
Transcription
1 573373TAR / Therapeutic Advances in Respiratory DiseaseC Howard, K Rangajhavala research-article2015 Therapeutic Advances in Respiratory Disease Original Research Pulmonary artery diastolic pressure as an indicator of severity of illness in patients with hypertension related to left-sided heart disease Ther Adv Respir Dis 2015, Vol. 9(2) DOI: / The Author(s), Reprints and permissions: journalspermissions.nav Christopher Howard, Kapil Rangajhavala and Zeenat Safdar Abstract Introduction: Pulmonary hypertension (PH) due to left-sided heart disease (Group 2 PH) is most commonly due to passive backward transmission of elevated left-sided heart pressures. A subgroup of these patients develop artery remodeling, resulting in systolic and mean artery pressures that are reactive or out of proportion to the elevated leftsided heart pressures. These patients have historically been identified by a (TPG) > 12 mmhg. However, since diastolic artery pressures are less susceptible to changes in blood flow, a diastolic (DPG) 7 mmhg may be a superior indicator of worse clinical function and prognosis. Methods: Based on measurements from a right-heart catheterization (RHC) database (Baylor College of Medicine, Houston, TX, USA), comparisons of several clinical parameters were made among three Group 2 PH patients: normal TPG and DPG (Group 2A), elevated TPG and normal DPG (Group 2B), and elevated TPG and DPG (Group 2C). Results: Among 173 RHCs, 39 were found to have Group 2 PH. Among these 39 cases, 10 (32%), 13 (32%), and 16 (36%) cases were categorized into Groups 2A, 2B, and 2C, respectively. Group 2C patients had significantly worse 6-min walk distance (308 ± 69 m) than Group 2A (425 ± 81 m) and Group 2B (350 ± 103 m) (p = 0.038). There was no significant difference in cardiac output, cardiac index, and right atrial pressure among the three subgroups. Discussion: Among patients with Group 2 PH, elevated DPG proved to be a more specific indicator of worse functional status than the historically used TPG. International guidelines and protocols for performing RHC for the assessment and diagnosis of PH should include the measurement of DPG. Keywords: diastolic, hypertension left-sided heart disease, Introduction Pulmonary hypertension (PH) is characterized by increased vascular resistance across the vascular bed usually as a result of vascular remodeling. It is defined by a mean artery pressure (PAP) of 25 mmhg at rest. Group 1 PH includes those patients who also have a arterial wedge pressure (PAWP) of 15 mmhg [Hoeper et al. 2013]. PH due to left-heart disease (Group 2 PH) is defined by a combination of mean PAP 25 mmhg, PAWP > 15 mmhg, and a normal or reduced cardiac output (CO) [Vachiéry et al. 2013]. It is most often characterized by postcapillary changes as a result of increased venous congestion that may be amenable to correction after the cause of left-heart disease has resolved. Over time, the venous congestion of a chronically elevated PAWP from left-sided heart disease, through a number of proposed complex mechanisms, appears to induce an additional secondary increase in mean PAP by way of vascular remodeling [West and Mathieu-Costello 1995; Kerem et al. 2010]. The term reactive or Correspondence to: Zeenat Safdar, MD, FACP, FCCP Associate Professor of Medicine, Director, Baylor Pulmonary Hypertension Program, Pulmonary- Critical Care Medicine, Baylor College of Medicine, Houston, TX 77030, USA safdar@bcm.edu Christopher Howard, MD Kapil Rangajhavala, MD Division of Pulmonary- Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA 35
2 Therapeutic Advances in Respiratory Disease 9(2) out-of-proportion PH has historically been used to describe these patients, and has been defined quantitatively by a (TPG) (mean PAP PAWP) of > 12 mmhg [Galiè et al. 2009]. Another pertinent hemodynamic parameter is the diastolic (DPG), which is defined as the difference between the artery diastolic pressure and PAWP. Hemodynamic analyses have indicated that DPG can distinguish between and cardiac disease [Stevens, 1975], and might be a better indicator of vascular disease since it is less sensitive to changes in cardiac pressures and flows than the often used TPG [Naeije et al. 2013; Capomolla et al. 2000]. PH due to left-heart disease is an increasingly common form of PH [Ghio et al. 2001; Lam et al. 2009], and is also an indicator of elevated mortality among patients with left-sided heart disease [Aronson et al. 2011], similar to those with PH in the setting of chronic lung disease such as fibrosis and chronic obstructive disease [Patel et al. 2007; Thabut et al. 2005]. Despite the suggested physiologic superiority of DPG versus TPG in indicating severity of vascular disease in Group 2 PH patients, analyses of the clinical implications of an elevated DPG versus TPG are sparse. The purpose of this analysis was to determine the clinical significance of an elevated DPG, defined as being 7 mmhg, among patients with Group 2 PH. Methods Hemodynamic data were obtained from the rightheart catheterizations (RHCs) of patients referred for PH evaluation. All consecutive patients undergoing RHC at Baylor College of Medicine (Houston, TX, USA), both outpatient and inpatient, between 2001 and 2007 were included in the study. RHCs were performed by one of two hypertension experts during the study period. Baseline demographic data, hemodynamic data, suspected etiology of PH, and outcomes data were collected. Patient data were excluded if profiles had inadequate data, or diagnoses of porto hypertension, congenital heart disease with intracardiac shunts, veno-occlusive disease, or exerciseinduced PH. A total of 173 patients underwent RHC, but 40 patients were removed from analysis due to having normal hemodynamics, incomplete data, exercised-induced PH, porto- hypertension, veno-occlusive disease, or congenital heart disease (Figure 1). Based on clinical and hemodynamic parameters, patients were categorized as normal, or having one of the five groups of PH, according to international PH guidelines [Hoeper et al. 2013]. Patients with PH and PAWP 15 mmhg at rest, but with exerciseinduced PAWP > 15 mmhg, were included and analyzed as having Group 2 PH. Among those who had exercise-induced Group 2 PH, hemodynamic values during exercise were used for analysis. Among those categorized as having Group 2 PH, patients were further subcategorized as: Group 2A (normal TPG and normal DPG), Group 2B (elevated TPG and normal DPG), or Group 2C (elevated TPG and elevated DPG). Pulmonary artery compliances (PAC) were measured by dividing the stroke volume (CO divided by heart rate) by the artery pulse pressure ( artery systolic minus diastolic pressure). Statistical analysis The means of basic demographic, hemodynamic, and clinical parameters were calculated for each group and subgroup of PH and then compared for statistically significant differences (data are presented as mean ± standard deviation). Significance testing was performed using the Mann Whitney/Wilcoxon signed-rank test, with p values < 0.05 considered to be statistically significant. For Group 2 PH patients, Spearman s rank correlation coefficient/linear regression was used to determine the correlation between vascular resistance (PVR) and DPG, and PVR and TPG. All statistical analyses were performed using Epi Info Results A total of 133 patients were included in the analysis and placed into PH Groups 1 5: 80 patients were categorized as Group 1 PH, 39 as Group 2 PH, and 14 combined into Groups 3 5 PH. The basic demographics of each group are described in Table 1. Approximately one-third (14 out of 39, 35.9%) of the patients with Group 2 PH met such criteria based on exercise-induced hemodynamic measurements. (Exercise testing included having patients perform 3 5 min of recumbent cycling, in order to achieve an increase in heart rate of beats/min above baseline.) When comparing the basic demographics of patients among groups with normal hemodynamics (n = 20), Group 1 PH (n = 80), Group 2 PH (n = 39), and Groups 3 5 PH (n = 14), there was a significant 36
3 C Howard, K Rangajhavala et al. Figure 1. Breakdown of right-heart catheterization data into hypertension groups. Table 1. Demographic data of patients in the right-heart catheterization database. NORMAL ( n = 20) GROUP 1 (n = 80) GROUP 2 (n = 39) GROUP 3-5 (n = 14) p value Age (years) 53.4 ± ± ± ± Gender F = 90% F = 88% F = 79% F = 46% Body mass index 28.8 ± ± ± ± (kg/m 2 ) Body surface area (m 2 ) 1.8 ± ± ± ± 0.3 < difference in age, gender, and body mass index (BMI)/body surface area (BSA) (Table 1). Table 2 shows the hemodynamic and clinical data of patients in the database that had normal hemodynamics or had Group 1 PH or Group 2 PH. Among those with Group 2 PH, 10, 13, and 16 patients had hemodynamic values consistent with Groups 2A, 2B, and 2C, respectively (Table 3). Among the subgroups of Group 2 PH, there was no significant difference in age, gender, or BMI/ BSA. When comparing the hemodynamic parameters among the three subgroups of Group 2 PH patients, there was no significant difference in heart rate, blood pressure, or right atrial pressure (Table 4). However, those with elevated TPG and DPG designated as Group 2C had significantly higher pressures and PVR (consistent with definition of these two parameters). There was no difference in PAWP, CO/cardiac index (CI), left ventricular ejection fraction (LVEF), or mixed venous saturation (SvO 2 ). Group 2C patients had significantly worse 6-min walk distance (6MWD) (308 ± 69 m) than Group 2A (425 ± 81 m) and Group 2B (350 ± 103 m) (p = 0.038). Although there was a trend towards Group 2C patients having a lower PAC, it did not 37
4 Therapeutic Advances in Respiratory Disease 9(2) Table 2. Hemodynamic and clinical data of patients in the right-heart catheterization database. NORMAL (n = 20) GROUP 1 (n = 80) GROUP 2 (n = 39) p value (Group 1 versus 2) Heart rate (beats/min) 66.7 ± ± ± Mean blood pressure 83.3 ± ± ± 20.8 < Right atrial pressure 7.0 ± ± ± Pulmonary arterial systolic pressure 27.6 ± ± ± 15.3 < Pulmonary arterial diastolic pressure 11.6 ± ± ± Pulmonary arterial mean pressure 17.0 ± ± ± 9.9 < Pulmonary arterial wedge pressure 11.8 ± ± ± 5.7 < Diastolic ± ± ± 9.3 < Trans 5.0 ± ± ± 10.9 < Cardiac output (L/min) 5.8 ± ± ± 1.9 < Cardiac index (L/min/m 2 ) 3.3 ± ± ± Left ventricular ejection function (%) 62.5 ± ± ± Pulmonary vascular resistance (WU) 1.0 ± ± ± 1.9 < Venous oxygen saturation (%) 71.9 ± ± ± min walk distance (m) ± ± ± Table 3. Demographic data of patients in the right-heart catheterization database with Group 2 hypertension. GROUP A Normal (n = 10) GROUP B (n = 13) GROUP C diastolic (n = 16) p value AGE (years) 60.6 ± ± ± Gender F = 84.6 % F= 55.6 % F = 87.5% Body mass 34.8 ± ± ± index(kg/m 2 ) Body surface area (m 2 ) 2.1 ± ± ± reach statistical significance. The mean DPG among Group 2C patients was 13.6 ± 6.4. Figure 2 demonstrates that among Group 2 PH patients in the RHC database, there was a significant correlation between PVR and both DPG and TPG. The correlation between PVR and DPG was stronger than that between PVR and TPG. Discussion This analysis indicates that in patients with Group 2 PH, DPG is a more specific indicator of worse clinical performance status compared with TPG, as demonstrated specifically by correlating with a significantly lower 6MWD. Despite the historical concerns about lack of consistency and specificity of the 6MWD as a testing modality, it remains one of the most important parameters for managing and monitoring disease severity in patients with PH. This superiority of DPG over TPG is significant because, among Group 2 PH patients, TPG has historically been a primary indicator of severity of disease and an identifier of patients who also have a component of precapillary PH. 38
5 C Howard, K Rangajhavala et al. Table 4. Hemodynamic and clinical data of patients in the right-heart catheterization database with Group 2 PH. GROUP A Normal (n = 10) GROUP B (n = 13) GROUP C diastolic (n = 16) p value Heart rate (beats/min) 71.7 ± ± ± Mean blood pressure 88.4 ± ± ± Right atrial pressure 11.0 ± ± ± Pulmonary arterial systolic 53.6 ± ± ± 13.2 < pressure Pulmonary arterial diastolic 22.3 ± ± ± 6.8 < pressure Pulmonary arterial mean 32.4 ± ± ± 8.3 < pressure Pulmonary arterial wedge 26.2 ± ± ± pressure Diastolic -3.9 ± ± ± 6.4 < Trans 6.2 ± ± ± 7.8 < Cardiac output (L/min) 5.9 ± ± ± Cardiac index (L/min/m 2 ) 2.6 ± ± ± Left ventricular ejection 62.5 ± ± ± function (%) Pulmonary vascular resistance 1.0 ± ± ± 1.4 < (WU) Venous oxygen saturation (%) 52.9 ± ± ± min walk distance (m) ± ± ± Pulmonary artery Compliance (ml/ mmhg) 2.59 ± ± ± Figure 2. Correlation between vascular resistance and diastolic versus among hypertension Group
6 Therapeutic Advances in Respiratory Disease 9(2) DPG also showed other unique and important characteristics. For example, when compared with patients with only elevated TPG, patients with an elevated DPG exhibited similar vascular dynamics to Group 1 PH patients in terms of PVR and pressure s. Those with a high DPG had a significantly higher PVR than other Group 2 PH patients, but otherwise had similar hemodynamics (PAWP, CO/CI, SvO 2, and LVEF). In addition, based on the DPG range in our Group 2C patients (95% confidence interval mmhg), a 7 mmhg appears to be an appropriate cutoff for specifying an elevated DPG. This cutoff is consistent with recently updated international guidelines [Vachiéry et al. 2013], which are partly based on a previous report indicating the same DPG-level cutoff as predictive of elevated mortality [Gerges et al. 2013]. One limitation cited in the recently updated guidelines for using DPG was that no patients with elevated DPG but normal TPG were available for analysis. However, our study addresses this concern in that there were no patients in this database with an elevated DPG but a normal TPG. This indicates that a high DPG reflects severity of disease along a spectrum in Group 2 PH patients, as opposed to an independent pathologic entity. Although these findings need to be confirmed with future studies, we recommend that DPG be routinely measured during RHCs and used for the identification of Group 2 PH patients with pre- and postcapillary PH. The limitations of this study include the inherent and well-known challenges of measuring hemodynamics during RHCs, even when performed by experts. Also, due to the retrospective methodology of this analysis, the duration, severity of disease, suspected etiology, and treatment regimens could not be prospectively evaluated or adjusted for completely. In addition, in reference to using exercise-induced measurements, exercise challenges were not routinely performed during all RHCs, and it is possible that among Group 2 PH patients, those that also have exercise-induced precapillary disease may not be the same as those with similar pathophysiology at rest. Acknowledgements Part of this study was presented at the American Thoracic Society Meeting, San Diego 2014 as an abstract format. Conflict of interest statement The authors declare no conflicts of interest in preparing this article. Funding This research received no specific grant from any funding agency in the public, commercial, or notfor-profit sectors. References Aronson, D., Eitan, A., Dragu, R. and Burger, A. (2011) Relationship between reactive hypertension and mortality in patients with acute decompensated heart failure. Circ Heart Fail 4: Capomolla, S., Febo, O., Guazzotti, G., Gnemmi, H., Mortara, A., Riccardi, G. et al. (2000) Invasive and noninvasive determinants of hypertension in patients with chronic heart failure. J Heart Lung Transplant 19: Galiè, N., Hoeper, M., Humbert, M., Torbicki, A., Vachiéry, J., Barberà, J. et al.; ESC/ERS Committee for Practice Guidelines (CPG). (2009) Guidelines for the diagnosis and treatment of hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30: Gerges, C., Gerges, M., Lang, M., Zhang, Y., Jakowitsch, J., Probst, P. et al. (2013) Diastolic vascular pressure. A predictor of prognosis in out-of-proportion hypertension. Chest 143: Ghio, S., Gavazzi, A., Campana, C., Inserra, C., Klersy, C., Sebastiani, R. et al. (2001) Independent and additive prognostic value of right ventricular systolic function and artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37: Hoeper, M., Bogaard, H., Condliffe, R., Frantz, R., Khanna, D., Kurzyna, M. et al. (2013) Definitions and diagnosis of hypertension. J Am Coll Cardiol 62: D42 D50. Kerem, A., Yin, J., Kaestle, S., Hoffmann, J., Schoene, A., Kuppe, H. et al. (2010) Lung endothelial dysfunction in congestive heart failure: role of impaired Ca2+ signaling and cytoskeletal reorganization. Circ Res 106: Lam, C., Borlaug, B., Kane, G., Enders, F., Rodeheffer, R. and Redfield, M. (2009) Age-associated 40
7 C Howard, K Rangajhavala et al. increases in artery systolic pressure in the general population. Circulation 119: Naeije, R., Vachiéry, J., Yerly, P. and Vanderpool, R. (2013) The pressure for the diagnosis of vascular disease. Eur Respir J 41: Patel, N., Lederer, D., Borczuk, A. and Kawut, S. (2007) Pulmonary hypertension in idiopathic fibrosis. Chest 132: Stevens, PM. (1975) Assessment of acute respiratory failure: cardiac versus causes. Chest 67: 1 2. Thabut, G., Dauriat, G., Stern, J., Logeart, D., Lévy, A., Marrash-Chahla, R. et al. (2005) Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 127: Vachiéry, J., Adir, Y., Barberà, J., Champion, H., Coghlan, J., Cottin, V. et al. (2013) Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 62: D100 D108. West, J. and Mathieu-Costello, O. (1995) Vulnerability of capillaries in heart disease. Circulation 92: Visit SAGE journals online SAGE journals 41
A critical appraisal of transpulmonary and diastolic pressure gradients
ORIGINAL RESEARCH Physiological Reports ISSN 2051-817X A critical appraisal of transpulmonary and diastolic pressure gradients M. Louis Handoko 1, Frances S. De Man 2,3, Frank P. T. Oosterveer 2, Harm-Jan
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST ESC Congress 2011 Pathophysiology of HFPEF Vascular Remodeling & Pulmonary Hypertension Carolyn S.P. Lam MBBS, MRCP, MS Case Presentation 81 yo woman with dyspnoea &
More informationPulmonary Hypertension: Definition and Unmet Needs
Heart Failure Center Hadassah University Hospital Pulmonary Hypertension: Definition and Unmet Needs Israel Gotsman The Heart Failure Center Hadassah University Hospital I DO NOT have a financial interest/
More informationRight Heart Catheterization. Franz R. Eberli MD Chief of Cardiology Stadtspital Triemli, Zurich
Right Heart Catheterization Franz R. Eberli MD Chief of Cardiology Stadtspital Triemli, Zurich Right Heart Catheterization Pressure measurements Oxygen saturation measurements Cardiac output, Vascular
More informationPULMONARY HYPERTENSION
PULMONARY HYPERTENSION REVIEW & UPDATE Olga M. Fortenko, M.D. Pulmonary & Critical Care Medicine Pulmonary Vascular Diseases Sequoia Hospital 650-216-9000 Olga.Fortenko@dignityhealth.org Disclosures None
More informationHALFWAY REVIEW REPORT
HALFWAY REVIEW REPORT Jakob Lundgren, MD, PhD student Pulmonary hypertension related to heart failure and hypoxia Mechanisms, new treatment strategies and impact on mortality following heart transplantation
More informationClinical Science Working Group 6: Diagnosis & Assessment of PAH. Co-chairs: David B. Badesch, MD Marius M. Hoeper, MD. Working Group 6 Members
Clinical Science Working Group 6: Diagnosis & Assessment of PAH Co-chairs: David B. Badesch, MD Marius M. Hoeper, MD Working Group 6 Members Harm Jan Bogaard, Robin Condliffe, Robert Frantz, Dinesh Khanna,
More informationΚαθετηριασμός δεξιάς κοιλίας. Σ. Χατζημιλτιάδης Καθηγητής Καρδιολογίας ΑΠΘ
Καθετηριασμός δεξιάς κοιλίας Σ. Χατζημιλτιάδης Καθηγητής Καρδιολογίας ΑΠΘ The increasing interest in pulmonary arterial hypertension (PAH), the increasing interest in implantation of LVADs, and the evolution
More informationPulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction
ORIGINAL ARTICLE PULMONARY VASCULAR DISEASE AND INTERSTITIAL LUNG DISEASE Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction Ganesh Raghu 1, Steven D. Nathan 2, Juergen
More informationChapter. Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension
Chapter 7 Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension P. Trip B. Girerd H.J. Bogaard F.S. de Man A. Boonstra G. Garcia M. Humbert D. Montani A. Vonk Noordegraaf Eur Respir
More informationTHE RIGHT VENTRICLE IN PULMONARY HYPERTENSION R. DRAGU
THE RIGHT VENTRICLE IN PULMONARY HYPERTENSION R. DRAGU Cardiology Dept. Rambam Health Care Campus Rappaport Faculty of Medicine Technion, Israel Why the Right Ventricle? Pulmonary hypertension (PH) Right
More informationPulmonary Hypertension Due to Left Heart Disease
ACC Middle East Conference 2018 Pulmonary Hypertension Due to Left Heart Disease Ammar Chaudhary, MBChB, FRCPC Advanced Heart Failure & Transplantation King Faisal Specialist Hospital and Research Center
More informationPulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University
Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of
More informationCharacterization of Patients With Borderline Pulmonary Arterial Pressure
[ Original Research Pulmonary Vascular Disease ] Characterization of Patients With Borderline Pulmonary Arterial Pressure Gabor Kovacs, MD ; Alexander Avian, PhD ; Maria Tscherner, MD ; Vasile Foris, MD
More informationIntroduction ... Aims. Methods and results
European Journal of Heart Failure (2017) doi:10.1002/ejhf.860 Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines
More informationDisclosures. Objectives. RV vs LV. Structure and Function 9/25/2016. A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension
Disclosures A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension No financial relationships Susan P. D Anna MSN, APN BC, CHFN September 29, 2016 Objectives RV vs LV Differentiate
More informationControversies in pulmonary hypertension due to left heart disease Martino Cheli 1 and Jean Luc Vachiery 2 *
Published: 05 January 2015 2015 Faculty of 1000 Ltd Controversies in pulmonary hypertension due to left heart disease Martino Cheli 1 and Jean Luc Vachiery 2 * Addresses: 1 Department of Internal Medicine,
More informationΠνευμονική υπέρταση: Τα 10 πιο σημαντικά κενά και παραλείψεις των Κατευθυντήριων Οδηγιών του 2015
Πνευμονική υπέρταση: Τα 10 πιο σημαντικά κενά και παραλείψεις των Κατευθυντήριων Οδηγιών του 2015 Γεωργία Γ. Πίτσιου, MD, MSc, PhD Πνευμονολόγος- Εντατικολόγος Επίκουρη Καθηγήτρια Ιατρική Σχολή ΑΠΘ Γ.Ν.
More informationPrognostic Factors for Survival in Pulmonary Hypertension Due to Left Heart Disease
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Pulmonary Circulation Prognostic Factors for Survival in Pulmonary Hypertension Due to
More informationAssessing the Impact on the Right Ventricle
Advances in Tricuspid Regurgitation Congress of the European Society of Cardiology (ESC) Munich, August 25-29, 2012 Assessing the Impact on the Right Ventricle Stephan Rosenkranz, MD Clinic III for Internal
More informationPrognostic factors in pulmonary arterial hypertension: Literature review
Reviews Prognostic factors in pulmonary arterial hypertension: Literature review Emilia Stępnowska 1, A, D, Ewa Lewicka 2, D, E, Alicja Dąbrowska-Kugacka 2, E, Paweł Miękus 1,F, Grzegorz Raczak 2, F 1
More informationDisclosures. Objectives 6/16/2016. A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension
A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension Susan P. D Anna MSN, APN-BC, CHFN June 24, 2016 Disclosures Objectives Differentiate structure and function of RV and LV
More informationPrecision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era.
1. Eur Respir Rev. 2018 Apr 13;27(148). pii: 180004. doi: 10.1183/16000617.0004-2018. Print 2018 Jun 30. Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the
More informationXiao-Ling Cheng, Zhi-Hong Liu, Qing Gu, Xin-Hai Ni, Zhi-Hui Zhao, Qin Luo, Jian-Guo He, Chang-Ming Xiong
Int J Clin Exp Med 2016;9(6):12091-12096 www.ijcem.com /ISSN:1940-5901/IJCEM0023007 Original Article Impact of systemic hypertension on clinical outcome of patients with idiopathic pulmonary arterial hypertension:
More informationThe right ventricle in chronic heart failure
The right ventricle in chronic heart failure ESC 2012 Christian Opitz, Berlin There are no conflicts of interest relevant to this presentation Percent of Population Prevalence of Heart Failure by Age and
More informationThe Hemodynamics of PH Interpreting the numbers
The Hemodynamics of PH Interpreting the numbers Todd M Bull MD Associate Professor of Medicine Division of Pulmonary Sciences and Critical Care Medicine Pulmonary Hypertension Center University of Colorado
More informationPulmonary Arterial Hypertension: Biomarkers and Treatment
Pulmonary Arterial Hypertension: Biomarkers and Treatment Demos Papamatheakis, MD Assistant Clinical Professor Division of Pulmonary, Critical Care and Sleep Medicine UC San Diego Health Definition EHJ
More informationIt has been more than a decade since
doi: 10.1111/j.1751-7133.2010.00192.x R EVIEW P APER Differentiating Pulmonary Arterial and Pulmonary Venous and the Implications for Therapy It has been more than a decade since the Second World Symposium
More informationDisclosures. Afterload on the PV loop. RV Afterload THE PULMONARY VASCULATURE AND ASSESSMENT OF THE RIGHT VENTRICLE
THE PULMONARY VASCULATURE AND ASSESSMENT OF THE RIGHT VENTRICLE Ryan J. Tedford, MD Heart Failure, Mechanical Circulatory Support, and Cardiac Transplantation Division of Cardiology, Department of Medicine
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationPulmonary Hypertension: Clinical Features & Recent Advances
Pulmonary Hypertension: Clinical Features & Recent Advances Lisa J. Rose-Jones, MD Assistant Professor of Medicine, Division of Cardiology Advanced Heart Failure/Cardiac Transplantation & Pulmonary Hypertension
More informationSubmaximal exercise pulmonary gas exchange in left heart disease patients with different forms of pulmonary hypertension
Submaximal exercise pulmonary gas exchange in left heart disease patients with different forms of pulmonary hypertension Short Title: Pulmonary gas exchange in HF patients with PH Authors: * Bryan J. Taylor,
More informationPVDOMICS. Study Introduction. Kristin Highland, MD Gerald Beck, PhD. NHLBI Pulmonary Vascular Disease Phenomics Program
PVDOMICS Study Introduction Kristin Highland, MD Gerald Beck, PhD NHLBI Pulmonary Vascular Disease Phenomics Program Funded by the National Heart, Lung, and Blood Institute of the National Institutes of
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationPulmonary hypertension in sarcoidosis
Pulmonary hypertension in sarcoidosis Olivier SITBON Centre de Référence de l Hypertension Pulmonaire Sévère Hôpital Universitaire de Bicêtre INSERM U999 Université Paris-Sud Le Kremlin-Bicêtre France
More informationPrognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies
Prognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies E. Beciani, M. Palazzini, C. Bachetti, F. Sgro, E. Conficoni, E.
More informationAtrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction
Atrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction JC Eicher, G Laurent, O Barthez, A Mathé, G Bertaux, JE Wolf Heart Failure Treatment Unit, Rhythmology and
More informationReal life management of CTEPH: patient case
2 nd International Congress on cardiovascular imaging in clinical practice k Real life management of CTEPH: patient case Anastasia Anthi Pulmonary Hypertension Clinic, Attikon University Hospital, Athens
More informationHemodynamic Evaluation of Pulmonary Hypertension in Chronic Kidney Disease
Hemodynamic Evaluation of Pulmonary Hypertension in Chronic Kidney Disease Ryan J. Tedford, MD Department of Medicine Division of Cardiology Johns Hopkins School of Medicine Baltimore, MD Paul R. Forfia,
More information22nd Annual Heart Failure 2018 an Update on Therapy. Pulmonary Arterial Hypertension: Contemporary Approach to Treatment
22nd Annual Heart Failure 2018 an Update on Therapy Pulmonary Arterial Hypertension: Contemporary Approach to Treatment Ronald J. Oudiz, MD, FACP, FACC, FCCP Professor of Medicine The David Geffen School
More informationHemodynamic Monitoring
Perform Procedure And Interpret Results Hemodynamic Monitoring Tracheal Tube Cuff Pressure Dean R. Hess PhD RRT FAARC Hemodynamic Monitoring Cardiac Rate and Rhythm Arterial Blood Pressure Central Venous
More informationAcute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction
Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction Marc A. Simon, 1,2,3,4 Rebecca R. Vanderpool, 2,3 Mehdi Nouraie,
More informationThe REDUCE LAP Heart Failure Trial. David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators
Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial David M Kaye
More informationPulmonary hypertension in the elderly: a different disease?
Grégory Berra 1, Stéphane Noble 2,3, Paola M. Soccal 1,2, Maurice Beghetti 2,4, Frédéric Lador 1,2 Frederic.Lador@hcuge.ch 1 Service de Pneumologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
More informationPVDOMICS. Study Introduction. Kristin Highland, MD Gerald Beck, PhD. NHLBI Pulmonary Vascular Disease Phenomics Program
PVDOMICS Study Introduction Kristin Highland, MD Gerald Beck, PhD NHLBI Pulmonary Vascular Disease Phenomics Program Funded by the National Heart, Lung, and Blood Institute of the National Institutes of
More informationCardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON
Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON Dunbar Ivy, MD The Children s s Hospital Heart Institute 1 Diagnostic Evaluation: Right Heart Cardiac
More informationUnder pressure: pulmonary hypertension associated with left heart disease
REVIEW PULMONARY HYPERTENSION Under pressure: pulmonary hypertension associated with left heart disease Harrison W. Farber 1 and Simon Gibbs 2 Affiliations: 1 Pulmonary Center, Boston University School
More informationLeft ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy
Left ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy Bogdan A. Popescu University of Medicine and Pharmacy Bucharest, Romania My conflicts of interest: I have
More informationPolicy Specific Section: May 16, 1984 April 9, 2014
Medical Policy Heart Transplant Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Transplant Original Policy Date: Effective Date: May 16, 1984 April 9, 2014 Definitions
More informationThe resistance-compliance product of the pulmonary circulation varies in health and pulmonary vascular disease
ORIGINAL RESEARCH Physiological Reports ISSN 2051-817X The resistance-compliance product of the pulmonary circulation varies in health and pulmonary vascular disease Charaka Hadinnapola 1, Qiuju Li 2,LiSu
More informationThe Case of Lucia Nazzareno Galiè, M.D.
The Case of Lucia Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationChronic Thromboembolic Pulmonary Hypertention CTEPH
Chronic Thromboembolic Pulmonary Hypertention CTEPH Medical Management Otto Schoch, Prof. Dr. Klinik für Pneumologie und Schlafmedizin Kantonsspital St.Gallen CTEPH: Medical Management Diagnostic aspects
More informationLong-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan
Original Article Acta Cardiol Sin 2017;33:498 509 doi: 10.6515/ACS20170612A Pulmonary Arterial Hypertension Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan
More informationELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY
ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY Contents Eligibility criteria for Pulmonary Arterial Hypertension therapy...2-6 Initial Application for funding of Pulmonary Arterial Hypertension
More informationAcute Vasodilator Testing in Pulmonary Hypertension: What, When, and How?
Acute Vasodilator Testing in Pulmonary Hypertension: What, When, and How? Teresa De Marco, MD University of California, San Francisco Disclosures: Grants/Research: United Therapeutics, Lung Biotechnology,
More informationInstructions: This form is completed and entered for all participants. Database will skip over sections that do not apply.
Revision of 08/30/2017 Form #102 Page 1 of 6 PVDOMICS STUDY PVD Assessment - Form #102 Instructions: This form is completed and entered for all participants. Database will skip over sections that do not
More informationThe Heart in Concert: Do Other Organs Matter? The Liver
The Heart in Concert: Do Other Organs Matter? The Liver Pascal de Groote CHRU Lille France DECLARATION OF CONFLICT OF INTEREST I have no conflict of interest with this presentation Impact of liver disease
More informationGlenn and Fontan Caths:
Glenn and Fontan Caths: Pre-operative evaluation and Trouble-shooting Cavo-Pulmonary Shunts Daniel H. Gruenstein, M.D. Director, Pediatric Interventional Cardiology University of Minnesota Children s Hospital,
More informationDr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college
Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college PULMONARY HYPERTENSION Difficult to diagnose early Because Not detected during routine physical examination and Even in advanced cases symptoms
More informationClinical implication of exercise pulmonary hypertension: when should we measure it?
Clinical implication of exercise pulmonary hypertension: when should we measure it? Jang-Young, Kim Wonju College of Medicine, Yonsei Univ. Exercise pulmonary hypertension (EPH) Introduction of pulmonary
More informationResting pulmonary artery pressure of mmhg predicts abnormal exercise haemodynamics
ERJ Express. Published on March 1, 16 as doi: 1.1183/139933.1684-15 ORIGINAL ARTICLE IN PRESS CORRECTED PROOF Resting pulmonary artery pressure of 21 24 mmhg predicts abnormal exercise haemodynamics Edmund
More informationThe growing interest in pulmonary hypertension (PH) in
Eur Respir J 2010; 36: 986 990 DOI: 10.1183/09031936.00038410 CopyrightßERS 2010 EDITORIAL Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed N. Galiè, M. Palazzini and
More informationMechanical Ventilation & Cardiopulmonary Interactions: Clinical Application in Non- Conventional Circulations. Eric M. Graham, MD
Mechanical Ventilation & Cardiopulmonary Interactions: Clinical Application in Non- Conventional Circulations Eric M. Graham, MD Background Heart & lungs work to meet oxygen demands Imbalance between supply
More informationUnexplained Pulmonary Hypertension in Elderly Patients* Brian P. Shapiro, MD; Michael D. McGoon, MD, FCCP; and Margaret M.
CHEST Unexplained Pulmonary Hypertension in Elderly Patients* Brian P. Shapiro, MD; Michael D. McGoon, MD, FCCP; and Margaret M. Redfield, MD Original Research PULMONARY HYPERTENSION Background: Idiopathic
More informationRaymond L. Benza, MD, a Mardi Gomberg-Maitland, MD, MSc, b Robert Naeije, MD, PhD, c Carl P. Arneson, MStat, d and Irene M.
http://www.jhltonline.org Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled
More informationPulmonary Arterial Hypertension: A Journey to Lung Transplant
PH GRAND ROUNDS Pulmonary Arterial Hypertension: A Journey to Lung Transplant Section Editor Deborah J. Levine, MD Bravein Amalakuhan, MD Pulmonary and Critical Care Medicine Fellow University of Texas
More informationPulmonary hypertension
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2012 Pulmonary hypertension Glaus, T M Posted at the Zurich Open Repository
More informationClinical Significance of Reactive Post-Capillary Pulmonary Hypertension in Patients With Left Heart Disease
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Pulmonary Circulation Clinical Significance of Reactive Post-Capillary Pulmonary Hypertension
More informationSerum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension*
CHEST Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension* Anna Fijalkowska, MD; Marcin Kurzyna, MD; Adam Torbicki, MD; Grzegorz Szewczyk, MD; Michał
More informationTopics to be Covered. Cardiac Measurements. Distribution of Blood Volume. Distribution of Pulmonary Ventilation & Blood Flow
Topics to be Covered MODULE F HEMODYNAMIC MONITORING Cardiac Output Determinants of Stroke Volume Hemodynamic Measurements Pulmonary Artery Catheterization Control of Blood Pressure Heart Failure Cardiac
More informationHeart Failure with Preserved Left Ventricular Ejection Fraction. (HFpEF)
Thessaloniki, May 27, 2017 Heart Failure with Preserved Left Ventricular Ejection Fraction Filippos Triposkiadis, MD, FESC, FACC Professor of Cardiology Director, Department of Cardiology Larissa University
More informationProf. Dr. Iman Riad Mohamed Abdel Aal
The Use of New Ultrasound Indices to Evaluate Volume Status and Fluid Responsiveness in Septic Shock Patients Thesis Submitted for partial fulfillment of MD degree in Anesthesiology, Surgical Intensive
More informationPROGNOSTIC VALUE OF THE PERSISTENCE OR CHANGE IN PERICARDIAL EFFUSION STATUS ON SERIAL ECHOCARDIOGRAMS IN PULMONARY ARTERIAL HYPERTENSION
PROGNOSTIC VALUE OF THE PERSISTENCE OR CHANGE IN PERICARDIAL EFFUSION STATUS ON SERIAL ECHOCARDIOGRAMS IN PULMONARY ARTERIAL HYPERTENSION by Zeina Abdulrazzak Dardari B.B.A., Cleveland State University,
More informationFUNDAMENTALS OF HEMODYNAMICS, VASOACTIVE DRUGS AND IABP IN THE FAILING HEART
FUNDAMENTALS OF HEMODYNAMICS, VASOACTIVE DRUGS AND IABP IN THE FAILING HEART CINDY BITHER, MSN, ANP, ANP, AACC, CHFN CHIEF NP, ADV HF PROGRAM MEDSTAR WASHINGTON HOSPITAL CENTER CONFLICTS OF INTEREST NONE
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationBrief View of Calculation and Measurement of Cardiac Hemodynamics
Cronicon OPEN ACCESS EC CARDIOLOGY Review Article Brief View of Calculation and Measurement of Cardiac Hemodynamics Samah Alasrawi* Pediatric Cardiologist, Al Jalila Children Heart Center, Dubai, UAE *
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationReal-world experience with riociguat in CTEPH
Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International
More informationTo Correlate Ejection Fraction with 6 Minute Walked Distance and Quality of Life in Patients with Left Ventricular Heart Failure
To Correlate Ejection Fraction with 6 Minute Walked Distance and Quality of Life in Patients with Left Ventricular Heart Failure Pramila S Kudtarkar*, Mariya P Jiandani*, Ashish Nabar** Abstract Purpose
More informationRevision of 10/27/2017 Form #280 Page 1 of 12 PVDOMICS STUDY Clinical Center Right Heart Catheterization (RHC) Results Form #280
Revision of 10/27/2017 Form #280 Page 1 of 12 PVDOMICS STUDY Clinical Center Right Heart Catheterization (RHC) Results Form #280 Instructions: Review PVDOMICS MOP Chapter 100 prior to completing right
More informationScreening for CETPH after acute pulmonary embolism: is it needed? Menno V. Huisman Department of Vascular Medicine LUMC Leiden
Screening for CETPH after acute pulmonary embolism: is it needed? Menno V. Huisman Department of Vascular Medicine LUMC Leiden m.v.huisman@lumc.nl Background CETPH Chronic Thrombo Embolic Pulmonary Hypertension
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationΜαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό
Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό Diastolic HF DD: Diastolic Dysfunction DHF: Diastolic HF HFpEF: HF with preserved EF DD Pathophysiologic condition: impaired relaxation, LV compliance, LV filling
More informationChallenging the 2015 PH Guidelines. Pulmonary Hypertension Definitions and Diagnosis Comments and Proposals
Challenging the 2015 PH Guidelines Pulmonary Hypertension Definitions and Diagnosis Comments and Proposals Professor Sean Gaine Mater Misericordiae University Hospital Dublin, Ireland Definitions and Diagnosis:
More informationComparison between adult and pediatric populations with I/HPAH and PAH-CHD in the Bologna ARCA registry
nazzareno.galie@unibo.it Comparison between adult and pediatric populations with I/HPAH and PAH-CHD in the Bologna ARCA registry Nazzareno Galiè, MD, FESC, FRCP (Hon), DIMES 2 Comprehensive clinical classification
More informationIncreased pulmonary artery diameter on chest computed tomography can predict borderline pulmonary hypertension
Research Article Increased pulmonary artery diameter on chest computed tomography can predict borderline pulmonary hypertension Tobias J. Lange 1, Christian Dornia 2, Jaroslava Stiefel 2, Christian Stroszczynski
More informationdifferent phenotypes
Pulmonary hypertension in scleroderma: different phenotypes UMR 995 Pr David LAUNAY, MD, PhD launayd@gmail.com Service de Médecine Interne. Unité d'immunologie Clinique CNRMR Maladies Systémiques et Autoimmunes
More informationUntreated idiopathic pulmonary arterial hypertension
Congenital Heart Disease Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension Delphine Yung, MD; Allison C. Widlitz, MS, PA; Erika Berman Rosenzweig, MD; Diane Kerstein, MD; Greg Maislin,
More informationTHE PROPER APPROACH TO DIAGNOSING HEART FAILURE WITH PRESERVED EJECTION FRACTION
THE PROPER APPROACH TO DIAGNOSING HEART FAILURE WITH PRESERVED EJECTION FRACTION James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine Disclosures Data
More informationPulmonary veno-occlusive disease
Disclosure Objectives Pulmonary veno-occlusive disease Tilman Humpl The Hospital for Sick Children University of Toronto, Canada Advisor/Research Grants Actelion Pfizer Historical aspects Epidemiology/Genetics
More informationPulmonary Hypertension Perioperative Management
Pulmonary Hypertension Perioperative Management Bruce J Leone, MD Professor of Anesthesiology Chief, Neuroanesthesiology Vice Chair for Academic Affairs Mayo Clinic Jacksonville, Florida Introduction Definition
More informationΕπεμβατικές στρατηγικές στην πνευμονική υπέρταση
Επεμβατικές στρατηγικές στην πνευμονική υπέρταση Παναγιώτης Καρυοφύλλης Καρδιολόγος Ωνάσειο Καρδιοχειρουργικό Κέντρο Mortality in PAH 2015 ESC/ERS Guidelines. Treatment algorithm Since BAS is performed
More informationInhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction
Inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction 4th Annual Pulmonary Hypertension Drug Discovery and Development Symposium July -, 7 Berlin,
More informationKeynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?
Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor
More informationDr.Fayez EL Shaer Consultant cardiologist Assistant professor of cardiology KKUH
Pulmonary Hypertension in patients with Heart Failure with Preserved Ejection Fraction Dr.Fayez EL Shaer Consultant cardiologist Assistant professor of cardiology KKUH Recent evaluation of available data
More informationFunctional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure
Research Article Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure Rudolf K. F. Oliveira 1,2,3, Mariana Faria-Urbina 1,2, Bradley A. Maron
More informationValidity of 6-min Walk Test in Assessment of Severity among Patients with Chronic Obstructive Pulmonary Disease
Original Article DOI: 10.17354/ijss/2016/14 Validity of 6-min Walk Test in Assessment of Severity among Patients with Chronic Obstructive Pulmonary Disease Lokendra Dave 1, Vivek Rajoriya 2, T N Dube 3,
More informationComparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension
Research Article Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension Ioana R. Preston, Kristen D. Sagliani, Kari E. Roberts,
More information